Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
TheBody.com/The Body PRO Covers The 48th Annual ICAAC/IDSA 46th Annual Meeting
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

RDEA Study Supports Further Development of New NNRTI

October 26, 2008

A study presented at the joint 2008 ICAAC/IDSA in Washington, DC supports the further development for RDEA806, an experimental NNRTI from Ardea Biosciences. Results from a phase 2a, 8-day monotherapy dose finding study were presented. Several doses, in both capsule and enteric-coated tablet formulations, were tested for absorption, drug interactions and anti-HIV activity.

Overall, people taking RDEA806 experienced drops in HIV levels of around 1.7 log. The responses were better at higher doses. The company has decided to proceed with testing 600, 800 and 1000mg enteric-coated tablets in its phase 2b studies, set to begin by the end of 2008.

There were no interactions between RDEA806 and either Viread (tenofovir) or Emtriva (emtricitabine). It does not interact with the CYP3A4 enzyme pathway, so it does not require Norvir boosting.

Advertisement
There were no moderate to severe (grade 3/4) adverse events reported in the study. No drug related rashes were reported, although the study might not have been long enough to detect such a problem.

After years of little development, the NNRTI class of HIV drugs -- which includes Sustiva (efavirenz), Viramune (nevirapine) and Intelence (etravirine) -- is finally seeing some new drug development. In addition to RDEA806, rilpivarine (TMC-278) and Idexa's IDX899 show promise. Widely considered more tolerable than protease inhibitors, NNRTIs have long been hampered by a high degree of cross-resistance leading most people to have only one shot at this class. All of these new drugs seem to overcome resistance to the first generation NNRTIs, giving many a second chance to take NNRTIs.


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
ICAAC/IDSA 2008 Newsroom



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement